+4.84%
last session
Amgen's stock is being driven by optimism around its GLP‑1 obesity drug MariTide and other growth drugs that could...
Sourcereuters.com - Jun 11
GLP-1 Stocks
HealthcareInnovationGrowth
Commercial GLP-1 leaders, next-generation metabolic drug developers, diabetes devices, and digital health platforms. The universe is dominated by GLP-1 Leaders (61%) and Devices & Adjacencies (20%), underperforming SPY by 17.7 percentage points YTD.
YTD Return
-9.8%
-17.7 pts vs SPY
4 of 23 beat SPY
1-Month Return
+8.5%
+8.6 pts vs SPY
Universe Size
23 Stocks
Curated theme basket
Market Cap
$2.85T
Total capitalization
Theme Performance
GLP-1 Stocks Performance vs SPY and QQQ
Track GLP-1 Stocks without checking every day
Weekly updates on performance, valuation changes, and key movers.
Theme Composition
GLP-1 Stocks Breakdown
Composition last reviewed
As of Jun 1, 2026
Categories reflect each company's primary theme role. Some companies may have exposure to multiple segments.
Theme Overview
GLP-1 Stocks Overview
A summary of how the theme breaks down across business segments and where concentration risk lives.
Selected Stocks
22
in theme
Total Market Cap
$2.65T
combined
Highly Concentrated
The top 2 segments (GLP-1 Leaders & Devices & Adjacencies & Tools & AI Discovery & Other segments) represent 86.6% of this theme by market cap.
Top GLP-1 Stocks Stocks
Top GLP-1 Stocks Stocks by Segment, Performance, and Valuation
LLY
Eli Lilly and Company
Price$1,160.95
Mkt Cap-
YTD+7.5%
Rev G47.4%
MRK
Merck & Co., Inc.
Price$120.78
Mkt Cap-
YTD+13.5%
Rev G1.2%
AMGN
Amgen Inc.
Price$354.06
Mkt Cap-
YTD+8.1%
Rev G9.1%
TMO
Thermo Fisher Scientific Inc.
Price$475.66
Mkt Cap-
YTD-19.7%
Rev G5.4%
ABT
Abbott Laboratories
Price$89.65
Mkt Cap-
YTD-27.8%
Rev G6.4%
PFE
Pfizer Inc.
Price$26.18
Mkt Cap-
YTD+4%
Rev G1.4%
ISRG
Intuitive Surgical, Inc.
Price$412.90
Mkt Cap-
YTD-26.5%
Rev G21.4%
DHR
Danaher Corporation
Price$180.79
Mkt Cap-
YTD-21.5%
Rev G4%
SYK
Stryker Corporation
Price$305.64
Mkt Cap-
YTD-12.2%
Rev G11.2%
MDT
Medtronic plc
Price$80.33
Mkt Cap-
YTD-16.4%
Rev G6.9%
| # | Chart (YTD) | |||||||
|---|---|---|---|---|---|---|---|---|
| 1 | LLY Eli Lilly and Company | $1,160.95 | $1.1T | +7.5% | +20% | 50.6 | 47.4% | |
| 2 | MRK Merck & Co., Inc. | $120.78 | $298.3B | +13.5% | +8.5% | 16.6 | 1.2% | |
| 3 | AMGN Amgen Inc. | $354.06 | $191.08B | +8.1% | +7.4% | 24.9 | 9.1% | |
| 4 | TMO Thermo Fisher Scientific Inc. | $475.66 | $176.77B | -19.7% | +5.1% | 26.8 | 5.4% | |
| 5 | ABT Abbott Laboratories | $89.65 | $155.89B | -27.8% | +8.6% | 11.7 | 6.4% | |
| 6 | PFE Pfizer Inc. | $26.18 | $148.89B | +4% | +1.4% | 19.2 | 1.4% | |
| 7 | ISRG Intuitive Surgical, Inc. | $412.90 | $146.65B | -26.5% | -1.7% | 52.5 | 21.4% | |
| 8 | DHR Danaher Corporation | $180.79 | $127.96B | -21.5% | +8.6% | 35.9 | 4% | |
| 9 | SYK Stryker Corporation | $305.64 | $117.06B | -12.2% | +8.2% | 36.4 | 11.2% | |
| 10 | MDT Medtronic plc | $80.33 | $103.13B | -16.4% | +7.8% | 22.3 | 6.9% |
Showing 10 of 22 stocks
Daily Intelligence
Yesterday in GLP-1 Stocks
Key headlines and stock-level catalysts from the last trading session.
Last session recap is current.
End-of-day analysis published after market close. Next update after Jun 12, 2026 market close.
Session Brief
Jun 12, 2026Obesity GLP‑1 stocks are driven by rising obesity rates, expanding indications, and new FDA approvals. Novo Nordisk’s Wegovy tablet UK approval fuels upside, while cyber‑security concerns dampen sentiment. Amgen’s Tavneos data reassessment signals potential volatility.
Key Drivers
Stock-Level Catalysts
Sentiment reflects catalyst narrative, not price direction - a stock can close lower while the fundamental driver is bullish.
+2.16%
last session
Eli Lilly's stock is buoyed by FDA approval of extended dosing for its eczema drug Ebglyss and its leading position...
Source247wallst.com - Jun 11
+1.41%
last session
Merck’s share price is supported by the recent announcement of its animal‑health acquisition of TARGAN and a breako...
Sourcezacks.com - Jun 11
+2.25%
last session
Pfizer’s $25B acquisition fuels growth prospects and a 6.7% dividend, but German pricing policy concerns dampen ent...
Sourcezacks.com - Jun 11
+0.58%
last session
Abbott's cancer diagnostics growth story is gaining traction, driving the stock's appeal despite a recent dip below...
Sourcezacks.com - Jun 10
Updated after market close
Jun 12, 2026
Valuation Pulse
Are GLP-1 Stocks cheap or expensive right now?
DCF valuations and Wall Street ratings across the theme.
Data as of Jun 12, 2026 (EOD)
22 stocks in theme - 13 with full coverage
DCF Valuation
(Intrinsic Value)13
of 22
covered
Undervalued
3(23%)
Fair Value
3(23%)
Overvalued
7(54%)
Top DCF Upside (Undervalued Only)
View allWall Street Consensus
(Price Targets)22
of 22
covered
Buy / Strong Buy
18(82%)
Hold
4(18%)
Sell / Strong Sell
0(0%)
Coverage Snapshot
Consensus is based on 22 stocks with analyst price targets. DCF analysis is based on 13 stocks with intrinsic value estimates.
Valuation Distribution
(22 covered stocks)Theme Valuation Score
2.1
Cheap
Scale: 1 (Cheap) to 5 (Expensive)
1
Bargain
6 stocks (27%)
>= +30%
2
Cheap
11 stocks (50%)
+10% to +30%
3
Fair
2 stocks (9%)
-10% to +10%
4
Expensive
2 stocks (9%)
-25% to -10%
5
Very Expensive
1 stocks (5%)
<= -25%
Valuation score blends Wall Street target upside at 65% weight and DCF upside at 35% weight when both are available; single-source covered stocks use the available signal. Higher score means more expensive.
Earnings Calendar
Upcoming Earnings in GLP-1 Theme
Companies reporting in the next 30 days. Earnings dates and estimates can change as reports approach.
No earnings scheduled
No earnings scheduled in the next 30 days.
Earnings calendar updates as reporting dates are confirmed.
Research & Methodology
How to evaluate GLP-1 Stocks
Methodology, investment thesis, and key risks for this theme.
Show DetailsHide Details
Research & Methodology
How to evaluate GLP-1 Stocks
Methodology, investment thesis, and key risks for this theme.
How we evaluate these stocks
Our methodology
We separate commercial GLP-1 leaders, pipeline challengers, suppliers, devices, and healthcare platforms. The analysis weighs prescription growth, clinical data, capacity, reimbursement, and valuation.
- Direct obesity or metabolic exposure must be material
- Commercial leaders are separated from pipeline-stage names
- Trial data and safety profile drive challenger value
- Manufacturing capacity and reimbursement matter
- Valuation is checked against product durability
Investment thesis
Why this theme exists
GLP-1 drugs are reshaping obesity, diabetes, and cardiometabolic care. The opportunity spans large pharma leaders, differentiated pipeline assets, manufacturing capacity, and adjacent healthcare models.
- Obesity treatment is a large and underpenetrated market
- Commercial leaders can scale multi-billion-dollar franchises
- Next-generation drugs compete on efficacy, dosing, and tolerability
- Manufacturing capacity can become a competitive advantage
- Adjacencies may benefit or face demand disruption
Key risks
What could go wrong
The market is large, but investment outcomes depend on safety, trial results, pricing, reimbursement, supply, and patent protection. Smaller challengers can move sharply on single catalysts.
- Clinical failures or safety issues can reset valuations
- Insurance coverage can limit market size
- Manufacturing constraints can cap revenue growth
- Competition can pressure pricing and share
- Pipeline-stage companies may need financing before approval
FAQ
Frequently asked questions
Common questions investors have about the GLP-1 Stocks theme.
01What are GLP-1 stocks?
GLP-1 stocks are companies involved in obesity, diabetes, or metabolic treatments using GLP-1 or related mechanisms, plus selected healthcare companies affected by obesity treatment demand.
02Which companies are the direct GLP-1 leaders?
The direct commercial leaders are the large pharmaceutical companies with marketed obesity or diabetes drugs and the manufacturing capacity to scale them. Pipeline-stage biotechs are higher-risk challengers rather than proven leaders.
03Are obesity biotech stocks risky?
Yes. Smaller pipeline companies can move sharply on trial results, safety data, financing, and regulatory updates.
04How is this different from biotech healthcare stocks?
The healthcare theme is broad. This page focuses specifically on obesity, GLP-1, metabolic health, and related second-order exposures.
05What should I compare first?
Start with market cap, revenue growth, profitability, return history, and valuation, then separate commercial products from pipeline-stage risk. For biotechs, trial data and cash runway matter heavily.
Related Themes
Continue from GLP-1 Stocks into adjacent themes
Curated theme paths that share catalysts, supply chains, or investor workflows with this page.
Biotech & Healthcare Stocks
46 stocksUS biotech and healthcare stocks screened by market data, analyst coverage, and pipeline depth — large-cap pharma, gene therapy, medical devices, and AI-driven drug discovery.
YTD: +4.5%
vs SPY: -0.0 pts
AI Stocks
39 stocksTrack US AI stocks with live market data, an equal-weight theme performance chart, daily theme intelligence, and a research-first stock table.
YTD: +40.6%
vs SPY: +0.3 pts
Robotics & Automation Stocks
25 stocksRobotics and automation stocks screened across industrial automation, surgical robots, warehouse systems, and AI-driven autonomous platforms with live market data.
YTD: +25.1%
vs SPY: +0.2 pts
Ready to screen these stocks?
Open the full screener pre-loaded with this theme's filters to sort, rank, and compare.
Updated daily•Free•No signup